Literature DB >> 20891036

Complications of sclerotherapy: an update.

Jean-Jérôme Guex1.   

Abstract

OBJECTIVES: To describe, determine the incidence of, and explain the adverse reactions associated with the use of sclerotherapy and sclerosing agents.
MATERIAL AND METHODS: Review of current literature and personal research, with special attention to the French registry of 12,173 sclerotherapy sessions.
RESULTS: The nature and incidence of side effects of sclerosing agents vary according to the injection form: liquid or foam. They must be differentiated from complications of the method, which are less specific and often related to an inappropriate technique. Severe adverse events are rare, especially in relation to the billions of injections administered.
CONCLUSION: Complications and side effects of sclerotherapy are uncommon; the method has demonstrated its safety, with 0.22% of complications per session with liquid sclerosant and 0.58% with foamed sclerosant, but several points remain unclear, and more research is needed. Patient's informed consent can be better obtained thanks to the current knowledge herein summarized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20891036     DOI: 10.1111/j.1524-4725.2009.01409.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  8 in total

Review 1.  [Guidelines for sclerotherapy of varicose veins : S2k guideline of the German Society of Phlebology (DGP) in cooperation with the following professional associations: DDG, DGA, DDG, BVP. German Version].

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

2.  [Foam sclerotherapy. Uses and indications in dermatology and phlebology].

Authors:  M Heck; J Faulhaber; F X Breu; S W Schneider
Journal:  Hautarzt       Date:  2012-06       Impact factor: 0.751

Review 3.  S2k guidelines: diagnosis and treatment of varicose veins.

Authors:  F Pannier; T Noppeney; J Alm; F X Breu; G Bruning; I Flessenkämper; H Gerlach; K Hartmann; B Kahle; H Kluess; E Mendoza; D Mühlberger; A Mumme; H Nüllen; K Rass; S Reich-Schupke; D Stenger; M Stücker; C G Schmedt; T Schwarz; J Tesmann; J Teßarek; S Werth; E Valesky
Journal:  Hautarzt       Date:  2022-04-19       Impact factor: 1.198

4.  Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison.

Authors:  Huyen Tran Ngoc Nguyen; Al-Niaimi Firas; Trung The Van
Journal:  Lasers Med Sci       Date:  2020-08-03       Impact factor: 3.161

Review 5.  Transcutaneous laser treatment of leg veins.

Authors:  Arne A Meesters; Luiza H U Pitassi; Valeria Campos; Albert Wolkerstorfer; Christine C Dierickx
Journal:  Lasers Med Sci       Date:  2013-11-13       Impact factor: 3.161

6.  Acute renal failure, microangiopathic haemolytic anemia, and secondary oxalosis in a young female patient.

Authors:  Karolina M Stepien; Peter Prinsloo; Tony Hitch; Thomas A McCulloch; Rebecca Sims
Journal:  Int J Nephrol       Date:  2011-07-19

Review 7.  Sclerotherapy in the treatment of varicose veins : S2k guideline of the Deutsche Gesellschaft für Phlebologie (DGP) in cooperation with the following societies: DDG, DGA, DGG, BVP.

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-12       Impact factor: 0.751

8.  A Novel Approach for the Treatment of Spider Veins.

Authors:  Mirsad Mujadzic; Edmond F Ritter; Kenna S Given
Journal:  Aesthet Surg J       Date:  2015-08-04       Impact factor: 4.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.